Author

Xiufeng Xu

AstraZeneca (Sweden)ORCID 0000-0003-3885-3271Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Abdel Wahad Bidar· 1 shared Amir Taheri‐GhahfarokhiiD· 1 shared Anders LundiniD· 1 shared Anna Schantz· 1 shared Babak Alaei-MahabadiiD· 1 shared Camilla Johansson· 1 shared Carla P. MartinsiD· 1 shared Elizabeth L. Hardaker· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Abdel Wahad Bidar

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

GenomicsbioRxivPreprintApr 6, 2020

ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment

Anders Lundin, Michelle J. Porritt, Himjyot Jaiswal…·Marcello Maresca

This paper introduces an inducible CRISPR-Cas9 system for preclinical drug discovery, enabling controlled genome editing in mice to model cancer and test therapies.

2 citations

mousehuman

𝕏 PostBluesky